In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
about
Effects of nilotinib on regulatory T cells: the dose mattersChemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemiaAMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedUpdate on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsDasatinib as a treatment for Duchenne muscular dystrophyActivation of tyrosine kinases by mutation of the gatekeeper threonineDiscovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsCrystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound stateResistant mutations in CML and Ph(+)ALL - role of ponatinib.Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaDasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsGrowth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugateRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionImatinib binding to human c-Src is coupled to inter-domain allostery and suggests a novel kinase inhibition strategyTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases.Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.New dosing schedules of dasatinib for CML and adverse event managementNew approved dasatinib regimen available for clinical use.Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibFirst-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.Trapping moving targets with small molecules.A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in miceEmerging drugs for chronic myeloid leukemia.
P2860
Q21245709-0026513A-A147-4CA8-B62F-BA64236A93D3Q24622397-8E9DB5E0-CD4E-4803-845F-1283ACACE4BEQ24651465-1C974D74-6452-4B9C-AF7E-424BD10E015BQ26738514-F55EA3E2-788D-434F-9FD8-7C4A9FB341FFQ26751285-67F57111-1DE5-42A6-B659-39E543EEB519Q27025242-37916D9C-E744-4BB2-978A-52960EDEFCD9Q27028181-666768C9-6E8C-4373-BC27-74F7F76E27BDQ27300846-65BFE6CC-2141-4524-B91B-78D888E9AAFEQ27652166-EF0EDC27-9558-4846-922C-BDFD41FFE742Q27660281-A4CCE0BF-EDFC-464F-9F46-75836ED8D3BDQ27675279-12B5743C-DC4C-4E95-AC79-C40563D23BEFQ27853085-E79E88A0-4A0A-4A50-8B32-6D92D754B8A5Q27853214-F88BF0BC-C557-4376-821E-3FB2EC9F7D70Q28069900-5380EFAD-ED8A-4092-A4AD-B3418FD7C447Q28079372-0BC8B9E9-3793-428F-9D57-833FC913A676Q28473957-9C86A549-E8E2-4205-B317-B0F260D7AE72Q28482297-B71AF58D-2720-449C-9E86-8A57E6161B1EQ28548366-3EF2DF60-C5A2-42FD-A009-29A6309D2BBAQ30008882-9AE5B06F-334E-4101-B32B-12D7C20503AFQ30242015-03229AE0-5A6F-432C-946C-409FA78E2EBEQ30836557-2FA340CB-3986-4F12-BA9F-F6DD19BEA06CQ31036423-5098A7C2-381E-4C36-99DA-4E3CC889E4DAQ33285468-AA6A5093-923C-4474-9D1A-10C4A0C8E306Q33383407-11CF375A-BB15-418A-9024-D280B82F0157Q33383640-378C106A-748A-46F7-BAAF-DCA653CD0B12Q33383954-494A6CCC-09BA-4CF4-9F5C-4452B370F610Q33384766-2FBA017A-8795-4B35-AFBD-6B0D8E896EB0Q33387519-869617FF-B80F-4CEA-A3D7-4324CC8DC7F1Q33391185-5E58357E-B338-467E-A157-4CD224466969Q33392977-AFC6B544-A2BE-40AB-90AB-3FD36142F6E7Q33397085-309B37C3-FABA-4979-911C-75B4BA1BA797Q33398183-CB9F3A53-34B1-4A68-884D-ECCC47F12E4FQ33398716-E4FD24C6-DCB5-4E88-8B75-F8CAE8C53800Q33399101-627713C6-5FCA-4464-BC6E-A2A701028CBAQ33401360-025A18DD-5C00-45AA-A620-DA1E0CA2CAE1Q33411792-8BD4D290-9AA9-489B-8434-1AA0B31D0A81Q33416438-6CBE272E-1ADE-4A80-A5F3-4234DD861722Q33428910-D2BE3934-3873-4E97-9E36-5771B3BE4E8EQ33510153-53F681AF-2264-4881-8D55-4FFB4643D321Q33536762-CF0B7F28-2C67-4687-AF37-A6E9CB8CDF34
P2860
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
In vitro activity of Bcr-Abl i ...... ant Abl kinase domain mutants.
@en
type
label
In vitro activity of Bcr-Abl i ...... ant Abl kinase domain mutants.
@en
prefLabel
In vitro activity of Bcr-Abl i ...... ant Abl kinase domain mutants.
@en
P2093
P1433
P1476
In vitro activity of Bcr-Abl i ...... ant Abl kinase domain mutants.
@en
P2093
Denise K Walters
Eric P Stoffregen
Francis Y Lee
Jürgen Mestan
Michael W N Deininger
Paul W Manley
Sandra W Cowan-Jacob
Taiping Jia
Thomas O'Hare
P304
P356
10.1158/0008-5472.CAN-05-0259
P407
P577
2005-06-01T00:00:00Z